Abiopharma

🔍 Chen Hung-Wen (Executive)

Company: Apollomics Inc. (APLM)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Acquired 5,000 shares of CLASS A ORDINARY SHARES (Direct)
  Date: 2026-06-15 | Code: M | equity_swap_involved: false | shares_owned_after: 148,334.00 | transaction_form_type: 4
• Holds 0 shares of CLASS A ORDINARY SHARES (Direct)
  Date: 2026-06-15 | Code: H | nature_of_ownership: Through King Regent Management Limited | shares_owned_after: 763,028.00 | Footnotes: F1
• Sold 5,000 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-15 | Code: M | equity_swap_involved: false | shares_owned_after: 5,000.00 | transaction_form_type: 4 | Footnotes: F2, F3, F3

Footnotes:

• F1: The reporting person is the sole director and shareholder of King Regent Management Limited and has voting and dispositive power over the shares held by King Regent Management Limited. Accordingly, Mr. Chen may be deemed to be the beneficial owner of such shares. Mr. Chen disclaims beneficial ownership of the securities held by King Regent Management Limited, except to the extent of his pecuniary interest therein.
• F2: Each restricted stock unit represents a contingent right to receive one Class A Ordinary Share.
• F3: RSUs were granted and previously reported on a Form 3 filed March 18, 2026 and a Form 3/A filed April 14, 2026. Of the initial RSU grant, 5,000 shares vested on each of February 9, 2026, March 15, 2026 and June 15, 2026, and an additional 5,000 shares will vest on September 15, 2026. This transaction represents the vesting of 5,000 RSUs on June 15, 2026.